Vaxxinity, Inc.

AC Immune's ACI-7104 Shows Promise in Phase II Parkinson's Disease Trial

- AC Immune's stock surged by over 20% following positive interim data from its Phase II VacSYn trial of ACI-7104.056 for Parkinson's disease. - The immunotherapy ACI-7104.056 induced a 16-fold increase in anti-alpha-synuclein antibodies compared to placebo after three immunizations. - The VacSYn trial is an adaptive, placebo-controlled study in early Parkinson’s patients, with plans to initiate Part 2 with up to 150 patients. - Interim results showed a positive safety profile with only transient injection site reactions and headaches reported as adverse events.